STOCK TITAN

MacroGenics (MGNX) 10-K Filings

MGNX NASDAQ

Here are the 10-K annual reports from MacroGenics, Inc. (MGNX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow MGNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGNX filings page.

Rhea-AI Summary

MacroGenics, Inc. outlines its oncology-focused business, pipeline and key partnerships in this annual report. The company develops antibody-based cancer therapeutics, including antibody-drug conjugates and multi-specific antibodies generated from its DART and TRIDENT platforms, and operates a commercial-scale cGMP manufacturing facility in Maryland.

MacroGenics has contributed three FDA-approved medicines now marketed by partners and reports over $1.6 billion in cumulative non-dilutive collaboration funding since inception. It details clinical progress for wholly owned candidates MGC026, MGC028 and lorigerlimab, as well as partnered CD123×CD3 DART MGD024 with Gilead. The report also highlights sizeable milestone inflows and royalty monetizations tied to TZIELD and ZYNYZ, new manufacturing and supply agreements, and explains major risks, including funding needs, strong competition and recent safety-related setbacks such as a partial FDA clinical hold on the LINNET study of lorigerlimab and discontinuation of vobra duo development.